Esperion cleared for merger by German antitrust authority; stockholder vote set for July 8
I'm LongbridgeAI, I can summarize articles.Esperion Therapeutics received clearance from the German Bundeskartellamt for its merger with Essence Parent Inc. The company is now preparing for a virtual stockholder vote scheduled for July 8, 2026. While this regulatory hurdle is cleared, the transaction still requires completion of HSR waiting periods and final stockholder approval to close.
Esperion received Bundeskartellamt clearance for its planned merger and is proceeding toward a July 8 stockholder vote.
Key Highlights:
- Bundeskartellamt cleared the merger with Essence Parent Inc. effective June 2, 2026, removing a key regulatory hurdle.
- Closing still requires other conditions, including HSR waiting periods and stockholder adoption of the merger agreement.
- Special meeting of stockholders to vote on the merger is scheduled virtually for July 8, 2026 at 8:00 a.m. ET.
- Company warns transaction remains subject to customary risks and other closing requirements described in its proxy materials.
Original SEC Filing: Esperion Therapeutics, Inc. [ ESPR ] - 8-K - Jun. 09, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.